Reason for request
- Re-assessment of the improvement in actual benefit at the applicant’s
Clinical Benefit
Clinical Added Value
| minor |
Au regard des nouvelles données disponibles, l’ipilimumab (YERVOY) conserve son amélioration du service médical rendu mineure (ASMR IV) dans la stratégie thérapeutique. |
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
1YVGEhGmBWE85kt9
